Inactive Instrument

News Corcept Therapeutics Nasdaq

Equities

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating	May. 02	MT
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22	May. 01	MT
Transcript : Corcept Therapeutics Incorporated, Q1 2024 Earnings Call, May 01, 2024	May. 01
Corcept: Q1 Earnings Snapshot	May. 01	AQ
Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	GL
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	AQ
Corcept Completes Enrollment in Phase 4 CATALYST Trial	Apr. 29	GL
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial	Apr. 29	CI
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call	Apr. 24	GL
Corcept Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing's syndrome	Apr. 23	AQ
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome	Apr. 22	GL
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	Apr. 22	CI
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)	Apr. 15	GL
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	Apr. 15	CI
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	GL
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	CI
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome	Apr. 01	GL
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	Apr. 01	CI
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Corcept Therapeutics Nasdaq

Equities

Summary

Filters